Ipsen media releases

Key highlights

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

– 27 April 2023 – 1 mins read

27 April 2023 – 1 mins read

Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance

Paris (France), 27 April 2023

Filter

Topics

Period

Filter by

Reset

Showing: 1 – 05 of 30 Press Releases

Show

Sort

Ipsen delivers strong H1 2022 results and upgrades its full-year guidance

– 28 July 2022

28 July 2022

Ipsen delivers strong H1 2022 results and upgrades its full-year guidance

Paris (France), 28 July 2022 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, presents its financial results for the first half of 2022:

Ipsen to acquire Epizyme, expanding its portfolio in oncology

– 27 June 2022

27 June 2022

Ipsen to acquire Epizyme, expanding its portfolio in oncology

PARIS, FRANCE & CAMBRIDGE, MASSACHUSETTS, 27 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) and Epizyme (Nasdaq: EPZM) today announced that they have entered into a definitive merger agreement under which Ipsen will acquire Epizyme. The transacti

Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury

– 09 June 2022

09 June 2022

Ipsen receives positive opinion in Europe for Dysport® in the management of urinary incontinence in adults with neurogenic detrusor overactivity due to multiple sclerosis or spinal cord injury

PARIS, FRANCE, 9 June 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that Dysport® (abobotulinumtoxinA) has received positive opinion in Europe for the management of urinary incontinence (UI) in adults with neurogenic detrusor overac

ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different tumor types including metastatic non-small cell lung cancer

– 27 May 2022

27 May 2022

ASCO 2022: New Cabometyx® data show encouraging results in monotherapy and in combination across different tumor types including metastatic non-small cell lung cancer

PARIS, FRANCE, 26 May 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s

$European Commission approves Cabometyx® as a second-line treatment for people living with radioactive iodine-refractory differentiated thyroid cancer$

– 03 May 2022

03 May 2022

European Commission approves Cabometyx® as a second-line treatment for people living with radioactive iodine-refractory differentiated thyroid cancer

PARIS, FRANCE, 3 May 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the European Commission (EC) has approved the use of Cabometyx® (cabozantinib) as a monotherapy for the treatment of adult patients with locally advanced o

1 … 3 4 5 6

Your dedicated contacts

Amy Wolf

Vice President, Corporate Brand Strategy and Communications

Ioana Piscociu

Senior Manager, Media Relations

Press Releases